P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这是一项ECOG协议。本研究的目的是评价紫杉醇与曲妥珠单抗联合给药的顺序，作为肿瘤过度表达HER-2的结节阳性乳腺癌患者辅助治疗的一部分。这项研究将比较佐剂阿霉素(ADR)和环磷酰胺(CTX)每三周一次，共四个周期，然后每周单独给予紫杉醇(紫杉醇)12周与曲妥珠单抗(HERCEP)与紫杉醇同时开始的方案的疗效和毒性。曲妥珠单抗在紫杉醇完成后开始治疗9个月，持续12个月

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an ECOG protocol. The purpose of this study is to evaluate the sequencing of paclitaxel administration with trastuzumab as part of the adjuvant treatment of patients with node positive breast cancer whose tumors overexpress HER-2. This study will compare the efficacy and toxicity of adjuvant doxorubicin (ADR) and cyclophosphamide (CTX) every three weeks for four cycles followed by paclitaxel (TAXOL) administered weekly for twelve weeks alone versus this regime with trastuzumab (HERCEP) to be started concurrent with paclitaxel. Followed by trastuzumab for nine months versus this regime with trastuzumab started after the completion of Paclitaxel and continuing for twelve months